Karyopharm Therapeutics (NASDAQ:KPTI) Releases Earnings Results, Beats Expectations By $0.10 EPS

Karyopharm Therapeutics (NASDAQ:KPTIGet Rating) released its earnings results on Thursday. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10, MarketWatch Earnings reports. During the same period in the previous year, the firm earned ($0.77) earnings per share.

KPTI stock traded down $0.66 during trading on Friday, reaching $6.08. The stock had a trading volume of 3,296,298 shares, compared to its average volume of 1,933,900. Karyopharm Therapeutics has a 52 week low of $4.42 and a 52 week high of $14.73. The stock’s 50 day moving average is $7.07 and its two-hundred day moving average is $7.64. The firm has a market cap of $482.87 million, a PE ratio of -4.14 and a beta of -0.16.

In other news, insider Sharon Shacham sold 6,707 shares of the firm’s stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $9.86, for a total value of $66,131.02. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael Kauffman sold 6,764 shares of the firm’s stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $9.86, for a total value of $66,693.04. The disclosure for this sale can be found here. In the last three months, insiders sold 19,122 shares of company stock worth $188,543. 10.24% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Karyopharm Therapeutics by 1.5% in the fourth quarter. BlackRock Inc. now owns 8,918,206 shares of the company’s stock worth $57,343,000 after buying an additional 127,888 shares during the period. Millennium Management LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $9,775,000. Geode Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 1,442,731 shares of the company’s stock worth $9,276,000 after purchasing an additional 35,574 shares in the last quarter. Nuveen Asset Management LLC grew its position in shares of Karyopharm Therapeutics by 5.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,184,310 shares of the company’s stock worth $6,715,000 after purchasing an additional 65,302 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Karyopharm Therapeutics by 4.7% during the third quarter. Bank of New York Mellon Corp now owns 302,501 shares of the company’s stock worth $1,760,000 after purchasing an additional 13,445 shares in the last quarter. 67.75% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group cut their target price on Karyopharm Therapeutics from $20.00 to $10.00 in a research note on Monday, April 11th. JPMorgan Chase & Co. raised Karyopharm Therapeutics from an “underweight” rating to a “neutral” rating and set a $8.00 price objective on the stock in a research report on Wednesday, February 9th. SVB Leerink dropped their price objective on Karyopharm Therapeutics from $8.00 to $6.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 2nd. StockNews.com assumed coverage on Karyopharm Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, HC Wainwright dropped their price objective on Karyopharm Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, March 18th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.57.

Karyopharm Therapeutics Company Profile (Get Rating)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Further Reading

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.